BIEL/Electrome: The Next UNICORN / $1B Startup
The Medvi Playbook Is Repeating — But With a Bigger Market and Stronger Tailwinds
Electrome is lining up EXACTLY like every med-tech breakout of the last decade — but with one massive difference: the entire platform sits on top of BIEL’s FDA-cleared PEMF technology.
Whoop had LeBron.
Hyperice had Mahomes.
Eight Sleep had A-Rod.
Levels had the influencer army.
Every one of those companies exploded AFTER celebrity validation.
Electrome already has Orel Hershiser — not as a mascot, but as an investor + strategic advisor. That’s a stronger role than most celebrity-backed med-techs ever get.
And here’s the part nobody seems to grasp:
Electrome’s credibility advantage comes directly from BIEL’s 30 years of clinical data and FDA clearances.
Electrome didn’t invent PEMF.
Electrome didn’t get the FDA clearances.
Electrome didn’t build the clinical foundation.
BIEL did.
Electrome is the front-end brand.
BIEL is the regulatory engine powering the entire thing.
The Medvi Playbook — And How It Maps Directly to BIEL/Electrome
1. Starting Point: A $20,000 Idea - A 20-Year Under-Valued Tech
Medvi began as a tiny, manual digital-health tool built with ~$20k.
BIEL/Electrome parallel:
BIEL spent decades under-capitalized, sitting on validated science waiting for the right platform partner. Electrome is that partner.
2. AI as the Core Engine
Medvi rebuilt itself around AI automation:
AI triage
AI intake
AI provider matching
AI back-office automation
This removed labor bottlenecks and unlocked exponential scale.
BIEL/Electrome parallel:
Electrome is applying AI to pain management:
AI pain assessment
AI therapy optimization
AI adherence tracking
AI-guided ActiPatch/RecoveryRx usage
BIEL’s hardware becomes the data-generating endpoint that Electrome’s AI learns from.
3. Hyper-Scalable Business Model
Medvi automated 70–90% of operational overhead, enabling:
rapid onboarding
low pricing
high margins
national expansion
BIEL/Electrome parallel:
ActiPatch is:
FDA-cleared
low-cost
high-margin
infinitely scalable
Electrome turns BIEL’s hardware into a software-scaled therapy, not a retail gadget.
4. Viral Adoption & Network Effects
Medvi grew because it reduced admin burden and integrated with EHRs.
BIEL/Electrome parallel:
Electrome is already inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country — something BIEL never achieved alone.
And the 3,700-store retail rollout gives BIEL national shelf presence for the first time.
Every new user - more data - smarter AI - better outcomes - more adoption. The same flywheel.
5. Revenue Explosion
Medvi’s revenue curve:
Year 1: < $1M
Years 2–3: multi-state expansion
Year 4+: enterprise + insurer deals
This pushed Medvi to a $1.8B valuation.
BIEL/Electrome parallel:
Electrome is positioned for:
VA expansion
insurer partnerships
employer health plans
global distribution (Taiwan already adopted ActiPatch)
AI-driven chronic-pain programs
This is the same revenue-acceleration zone Medvi entered before its breakout.
The Celebrity-Validation Effect — And Why It Benefits BIEL Most
1. Electrome’s credibility = BIEL’s credibility
Electrome is being praised for having what Whoop, Hyperice, Eight Sleep, and Levels didn’t: FDA-cleared tech.
That FDA clearance is BIEL’s.
Every time Electrome gets attention, the underlying message is:
“This tech is real, regulated, and safe.”
That is BIEL’s moat.
2. Electrome will expand the PEMF category — and BIEL is the cheapest FDA-cleared PEMF device in the market
Electrome drives awareness.
BIEL captures spillover demand.
This is the same pattern that made:
Hyperice explode recovery
Whoop explode biometrics
Eight Sleep explode sleep-tech
Electrome is about to do that for PEMF — and BIEL is the only FDA-cleared PEMF product at consumer price points.
3. Celebrity validation + FDA clearance is the historical trigger for med-tech breakouts
Electrome has:
celebrity validation
regulatory legitimacy
retail rollout timing
This is the same setup that preceded:
Hyperice’s unicorn jump
Whoop’s $3.6B valuation
Eight Sleep’s $500M valuation
Except Electrome’s foundation is stronger because it’s built on FDA-cleared PEMF — and that clearance belongs to BIEL.
4. BIEL is the “Intel Inside” of Electrome
Electrome is the brand.
BIEL is the technology.
Electrome’s success doesn’t dilute BIEL — it amplifies it.
For the first time in BIEL’s 20-year history:
a celebrity investor is validating the tech
a modern brand is commercializing it
a retail rollout is coming
a narrative is forming around FDA-cleared PEMF
BIEL has never had this kind of tailwind.
Conlusion:
BIEL/Electrome Are Following the Medvi Playbook — But With a Bigger Market and Stronger Tailwinds
Medvi proved that:
AI + healthcare + data flywheel = exponential value creation.
BIEL/Electrome are now executing the same model, but with:
FDA-cleared hardware
a global distribution partner
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
and a platform that scales like software
This is the strongest alignment of catalysts BIEL has seen in over a decade — and the closest real-world analog is Medvi’s $1.8B rise.
Electrome’s rise IS BIEL’s inflection point.
The market hasn’t priced that in yet.
The Medvi Playbook Is Repeating — But With a Bigger Market and Stronger Tailwinds
Electrome is lining up EXACTLY like every med-tech breakout of the last decade — but with one massive difference: the entire platform sits on top of BIEL’s FDA-cleared PEMF technology.
Whoop had LeBron.
Hyperice had Mahomes.
Eight Sleep had A-Rod.
Levels had the influencer army.
Every one of those companies exploded AFTER celebrity validation.
Electrome already has Orel Hershiser — not as a mascot, but as an investor + strategic advisor. That’s a stronger role than most celebrity-backed med-techs ever get.
And here’s the part nobody seems to grasp:
Electrome’s credibility advantage comes directly from BIEL’s 30 years of clinical data and FDA clearances.
Electrome didn’t invent PEMF.
Electrome didn’t get the FDA clearances.
Electrome didn’t build the clinical foundation.
BIEL did.
Electrome is the front-end brand.
BIEL is the regulatory engine powering the entire thing.
The Medvi Playbook — And How It Maps Directly to BIEL/Electrome
1. Starting Point: A $20,000 Idea - A 20-Year Under-Valued Tech
Medvi began as a tiny, manual digital-health tool built with ~$20k.
BIEL/Electrome parallel:
BIEL spent decades under-capitalized, sitting on validated science waiting for the right platform partner. Electrome is that partner.
2. AI as the Core Engine
Medvi rebuilt itself around AI automation:
AI triage
AI intake
AI provider matching
AI back-office automation
This removed labor bottlenecks and unlocked exponential scale.
BIEL/Electrome parallel:
Electrome is applying AI to pain management:
AI pain assessment
AI therapy optimization
AI adherence tracking
AI-guided ActiPatch/RecoveryRx usage
BIEL’s hardware becomes the data-generating endpoint that Electrome’s AI learns from.
3. Hyper-Scalable Business Model
Medvi automated 70–90% of operational overhead, enabling:
rapid onboarding
low pricing
high margins
national expansion
BIEL/Electrome parallel:
ActiPatch is:
FDA-cleared
low-cost
high-margin
infinitely scalable
Electrome turns BIEL’s hardware into a software-scaled therapy, not a retail gadget.
4. Viral Adoption & Network Effects
Medvi grew because it reduced admin burden and integrated with EHRs.
BIEL/Electrome parallel:
Electrome is already inside the U.S. Department of Veterans Affairs, the largest healthcare system in the country — something BIEL never achieved alone.
And the 3,700-store retail rollout gives BIEL national shelf presence for the first time.
Every new user - more data - smarter AI - better outcomes - more adoption. The same flywheel.
5. Revenue Explosion
Medvi’s revenue curve:
Year 1: < $1M
Years 2–3: multi-state expansion
Year 4+: enterprise + insurer deals
This pushed Medvi to a $1.8B valuation.
BIEL/Electrome parallel:
Electrome is positioned for:
VA expansion
insurer partnerships
employer health plans
global distribution (Taiwan already adopted ActiPatch)
AI-driven chronic-pain programs
This is the same revenue-acceleration zone Medvi entered before its breakout.
The Celebrity-Validation Effect — And Why It Benefits BIEL Most
1. Electrome’s credibility = BIEL’s credibility
Electrome is being praised for having what Whoop, Hyperice, Eight Sleep, and Levels didn’t: FDA-cleared tech.
That FDA clearance is BIEL’s.
Every time Electrome gets attention, the underlying message is:
“This tech is real, regulated, and safe.”
That is BIEL’s moat.
2. Electrome will expand the PEMF category — and BIEL is the cheapest FDA-cleared PEMF device in the market
Electrome drives awareness.
BIEL captures spillover demand.
This is the same pattern that made:
Hyperice explode recovery
Whoop explode biometrics
Eight Sleep explode sleep-tech
Electrome is about to do that for PEMF — and BIEL is the only FDA-cleared PEMF product at consumer price points.
3. Celebrity validation + FDA clearance is the historical trigger for med-tech breakouts
Electrome has:
celebrity validation
regulatory legitimacy
retail rollout timing
This is the same setup that preceded:
Hyperice’s unicorn jump
Whoop’s $3.6B valuation
Eight Sleep’s $500M valuation
Except Electrome’s foundation is stronger because it’s built on FDA-cleared PEMF — and that clearance belongs to BIEL.
4. BIEL is the “Intel Inside” of Electrome
Electrome is the brand.
BIEL is the technology.
Electrome’s success doesn’t dilute BIEL — it amplifies it.
For the first time in BIEL’s 20-year history:
a celebrity investor is validating the tech
a modern brand is commercializing it
a retail rollout is coming
a narrative is forming around FDA-cleared PEMF
BIEL has never had this kind of tailwind.
Conlusion:
BIEL/Electrome Are Following the Medvi Playbook — But With a Bigger Market and Stronger Tailwinds
Medvi proved that:
AI + healthcare + data flywheel = exponential value creation.
BIEL/Electrome are now executing the same model, but with:
FDA-cleared hardware
a global distribution partner
VA deployments
celebrity investor validation
international adoption
a massive unmet need (chronic pain)
and a platform that scales like software
This is the strongest alignment of catalysts BIEL has seen in over a decade — and the closest real-world analog is Medvi’s $1.8B rise.
Electrome’s rise IS BIEL’s inflection point.
The market hasn’t priced that in yet.
1
